APR 15·GlobeNewswireMed
Virbac: In the first quarter of 2025, revenue recorded solid growth of +4.9% at constant exchange rates and scope
In the first quarter of 2025, revenue recorded solid growth of +4.9% at constant exchange rates and scope ...
StockHealthcare · Drug Manufacturers - General
$VRBCF
Virbac SA/ADR
Price · $VRBCFvia TradingView
AI sentiment · 7d0 articles
No enriched coverage for $VRBCF in the last 7 days.
Insider · 30dFeed →
No SEC Form 4 filings for $VRBCF in the last 30 days.
Top stories · $VRBCFMore →